Skip to main content
SpringerLink
Log in

Staging and Treatment for Small Cell Lung Cancer

  • Conference paper
Current Topics in Lung Cancer

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

Abstract

Small cell lung cancer (SCLC) should be regarded as a systemic disease for which systemic therapy, i.e., chemotherapy, is considered as the cornerstone of treatment. Exact anatomical staging is only necessary if this influences treatment decisions in the individual patient, for instance radiotherapy or surgery. Furthermore, it is necessary for clinical trials to improve and facilitate comparison of different trials and interpretation of results. The simple staging system, introduced by the Veterans Administration Lung Cancer Study Group (VALG), of “limited” and “extensive” disease (Table 1) is still valuable for daily clinical practice [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Zeien M: Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 1973 (4 part 3):31–42.

    Google Scholar 

  2. Mountain CF: A new international staging system for lung cancer. Chest 1986 (89): 225–235.

    Google Scholar 

  3. Aisner J, Whitley NO: Staging of small cell lung cancer: do we need a new staging system? Lung Cancer 1989 (5):163–172.

    Article  Google Scholar 

  4. Souhami RL, Bradbury I, Geddes DM, et al: Prognostic significance of laboratory parameters measured at diagnosis of small cell carcinoma of the lung. Cancer Res 1985 (45): 2878–2882.

    PubMed  CAS  Google Scholar 

  5. Mangum MD, Greco FA, Hainsworth JD, Hande KR, Johnson DH: Combined small-cell and non-small-cell lung cancer. J Clin Oncol 1989 (7): 607–612.

    PubMed  CAS  Google Scholar 

  6. Chang AE, Schauer EG, Conkle DM, et al: Evaluation of computed tomography in the detection of pulmonary metastases. Cancer 1979 (43): 913–916.

    Article  PubMed  CAS  Google Scholar 

  7. Martini N, Heelan R, Westcott J, et al: Comparative merits of conventional computed tomographic and MRI in assessing mediastinal involvement in surgically confirmed lung carcinoma. J Thorac Cardiovasc Surg 1985 (90):639–648.

    PubMed  CAS  Google Scholar 

  8. Bye PTP, Harvey HPB, Woolcock AJ, et al: Fiberoptic bronchoscopy in small cell lung cancer: Findings pre-and postchemotherapy. Aust N Z J Med 1980 (10):397–400.

    Article  PubMed  CAS  Google Scholar 

  9. Stahel R, Aisner J, Ginsberg R, et al: Staging and prognostic factors in small cell lung cancer. Lung Cancer 1989 (5):119–126.

    Article  Google Scholar 

  10. Ihde DC, Simms EB, Matthews MJ, et al: Bone marrow metastases in small cell carcinoma of the lung: frequency, description, and influence on chemotherapeutic toxicity and prognosis. Blood 1979 (53):677–686.

    PubMed  CAS  Google Scholar 

  11. Hirsch FR: Histopathologic Classification and Metastatic Pattern of Small Cell Carcinoma of the Lung. With Special Reference to the Clinical Implications. Munksgaard, Copenhagen 1983.

    Google Scholar 

  12. Tritz DB, Doll DC, Ringenberg OS, et al: Bone marrow involvement in small cell lung cancer. Clinical significance and correlation with routine laboratory variables. Cancer 1989 (63):763–766.

    Article  PubMed  CAS  Google Scholar 

  13. Hirsch FR, Hansen HH, Hainau B: Bilateral bonemarrow examination in the staging of small-cell anaplastic carcinoma of the lung. Acta Pathol Microbiol Scan 1979 (87): 59–62.

    CAS  Google Scholar 

  14. Berendsen HH, De Leij L, Postmus PE, et al: Detection of small cell lung cancer metastases in bone marrow aspirates using monoclonal antibody directed against neuroendocrine differentiation antigen. J Clin Pathol 1988 (41):273–276.

    Article  PubMed  CAS  Google Scholar 

  15. Carney DN, Redmond O, Harford P, et al: Bone marrow involvement by small cell lung cancer using magnetic resonance imaging. Lung Cancer 1988 (4 suppl):A45.

    Article  Google Scholar 

  16. Levenson RM, Sauerbrunn BJL, Ihde DC, et al: Small cell lung cancer: radionuclide bone scans for assessment of tumor extent and response. Am J Radiol 1981 (137):31–35.

    Google Scholar 

  17. Dombermowsky P, Hirsch FR, Hansen HH, et al: Peritoneoscopy in the staging of 190 patients with small cell anaplastic carcinoma of the lung with special reference to subtyping. Cancer 1978 (41):2008–2012.

    Article  Google Scholar 

  18. Jensen LI, Hirsch FR, Thomsen C, et al: The diagnostic value of CT-scanning in detecting abdominal metastases from small cell lung carcinomas compared to ultrasonography. Lung Cancer 1988 (4 suppl):A45.

    Article  Google Scholar 

  19. Jensen LI, Hirsch FR, Peters K, et al: Extrahepatic abdominal metastases in small cell carcinoma of the lung. A comparison of CT-scanning and ultrasonography. In press.

    Google Scholar 

  20. Bunn PA, Rosen ST: Central nervous system manifestations of small cell lung cancer. In: Aisner J (ed) Lung Cancer. Churchill-Livingston, 1985 pp 287–305.

    Google Scholar 

  21. DiChiro G, Schellinger D: Computed tomography of spinal cord after lumbar intrathecal introduction of metrizamide: computed assisted myelography. Radiology 1976 (120):101–104.

    PubMed  Google Scholar 

  22. Pedersen AG, Becker KL, Back F, et al: Cerebrospinal fluid bombesin and calcitonin in patients with central nervous system metastases from small cell lung cancer. J Clin Oncol 1986 (4):1620–1627.

    PubMed  CAS  Google Scholar 

  23. Pedersen AG, Bach FW, Nissen M, et al: Creatine kinase BB and beta-2-microglobulin as markers of CNS-metastases in patients with small cell lung cancer. J Clin Oncol 1985 (3): 1364–1372.

    PubMed  CAS  Google Scholar 

  24. Cohen MH, Makuch R, Johnston-Early A, et al: Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Cancer Treat Rep 1981 (65):187–195.

    PubMed  CAS  Google Scholar 

  25. Osterlind K, Ihde DC, Ettinger DS, et al. Staging and prognostic factors in small cell carcinoma of the lung. Cancer Treat Rep 1983 (67):3–9.

    PubMed  CAS  Google Scholar 

  26. Ihde DC, Makuch RW, Carney DN, et al: Prognostic implications of stage of disease and sites of metastases in patients with small cell carcinoma of the lung treated with intensive combination therapy. Am Rev Respir Dis 1981 (123):500–507.

    PubMed  CAS  Google Scholar 

  27. Spiegelman D, Maurer LH, Ware JH, et at: Prognostic factors in small cell carcinoma of the lung: An analysis of 1,521 patients. J Clin Oncol 1989 (7):344–354.

    PubMed  CAS  Google Scholar 

  28. Osterlind K, Anderson PK: Prognostic factors in small cell lung cancer: A multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 1986 (46):4189–4194.

    PubMed  CAS  Google Scholar 

  29. Vincent MD, Ashley SE, Smith IE: Prognostic factors in small cell lung cancer: A simple prognostic index is better than conventional staging. Eur J Cancer Clin Oncol 1987 (23): 1589–1599.

    Article  PubMed  CAS  Google Scholar 

  30. Albain KS, Cowley JJ, LeBlanc M, Livingston RB: Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient southwest oncology group data base. J Clin Oncol 1990 (8):1563–1574.

    PubMed  CAS  Google Scholar 

  31. Cerney T, Blair V, Anderson H, et al: Pretreatment prognostic factors and scoring system in 407 small cell lung cancer patients. Int J Cancer 1987 (39):146–149.

    Article  Google Scholar 

  32. Sagman U, Feld R, De Boer G, et al: Long-term survival of patients with small cell lung cancer — The Toronto experience (1976–1986). Proc ASCO 1988 (7):203 (abstract).

    Google Scholar 

  33. Abrams J, Doyle LS, Aisner J: Staging, prognostic factors, and special considerations in small cell lung cancer. Semin Oncol 1988 (15):261–277.

    PubMed  CAS  Google Scholar 

  34. Osterlind K, Hansen HH, Hansen M, et at: Longterm disease-free survival in small-cell carcinoma of the lung: A study of clinical determinants. J Clin Oncol 1986 (4): 1307–1313.

    PubMed  CAS  Google Scholar 

  35. Ettinger DS: Evaluation of new drugs in untreated patients with small-cell lung cancer: Its time has come. Editorial. J Clin Oncol 1990 (8): 374–377.

    CAS  Google Scholar 

  36. Pedersen AG, Kristjansen PEG, Hansen HH: Prophylactic cranial irradiation and small cell lung cancer. Cancer Treat Rev 1988 (15):85–103.

    Article  PubMed  CAS  Google Scholar 

  37. Green RA, Humphrey E, Close H, et al: Alkylating agents in bronchogenic carcinoma. Am J Med 1969 (40):360–367.

    Google Scholar 

  38. Bork E, Hansen M, Dombermowsky P, Hansen SW, Pedersen AG, Hansen HH: Teniposide (VM 26), an overlooked highly active agent in small cell lung cancer. Results of a phase II trial in untreated patients. J Clin Oncol 1986 (4):524–527.

    PubMed  CAS  Google Scholar 

  39. Smit EF, Carney DN, Harford P, Sleijfer DT, Postmus PE: A phase II study of oral etoposide in elderly patients with small cell lung cancer. Thorax 1989 (44):631–633.

    Article  PubMed  CAS  Google Scholar 

  40. Slevin ML, Clark PI, Joel S, et al: A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncot 1989 (7): 1333–1340.

    CAS  Google Scholar 

  41. Mclllmurray MB, Bibby, RJ, Taylor BE, et al: Etoposide compared with the combination of vincristine, doxorubicin, and cyclophosphamide in the treatment of small cell lung cancer. Thorax 1989 (44):215–219.

    Article  Google Scholar 

  42. Shields TW, Higgins GA, Matthews MJ, et al: Surgical resection in the management of small cell carcinoma of the lung. J Thorac Cardiovasc Surg 1982 (84):481–488.

    PubMed  CAS  Google Scholar 

  43. Perry MC, Eaton WL, Propert KJ, et al: Chemotherapy with or without radiation therapy in limited small cell carcinoma of the lung. N Engl J Med 1987 (316):912–918.

    Article  PubMed  CAS  Google Scholar 

  44. Bunn PA, Lichter AS, Makuch RW, et al: Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer. Ann Intern Med 1987 (106):655–662.

    PubMed  Google Scholar 

  45. Osterlind K, Hansen HH, Hansen HS, et al: Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer. Results of a controlled trial with 5 year follow-up. Br J Cancer 1986 (54):7–17.

    Article  PubMed  CAS  Google Scholar 

  46. Perez CA, Einhorn L, Oldham RK, et al: Randomized trial of radiotherapy to the thorax in limited small cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: A preliminary report. J Clin Oncol 1984 (2):1200–1208.

    PubMed  CAS  Google Scholar 

  47. Kies MS, Mira JG, Crowley JJ, et al: Multimodal therapy for limited small cell lung cancer: A randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partical responders: A Southwest Oncology Group Study. J Clin Oncol 1987 (5):592–600.

    PubMed  CAS  Google Scholar 

  48. Fox RM, Woods RL, Brodie GN, et al: A randomized study: small cell anaplastic lung cancer treated by combination chemotherapy and adjuvant radiotherapy. Int J Radiat Oncol Biol Phsy 1980 (6):1083–1085.

    Article  CAS  Google Scholar 

  49. Souhami RL, Geddes DM, Spiro SG, et al: Radiotherapy in small cell cancer of the lung treated with combination chemotherapy: A controlled trial. Br Med J 1984 (288): 1643–1646.

    Article  CAS  Google Scholar 

  50. Nou E, Brodin O, Bergh J: A randomized study of radiation treatment in small cell bronchial carcinoma treated with two types of four-drug chemotherapy regimens. Cancer 1988 (62):1079–1090.

    Article  PubMed  CAS  Google Scholar 

  51. Holoye PY, McMurtrey MJ, Mountain CF, et al: The role of adjuvant surgery in the combined modality therapy of small-cell bronchogenic carcinoma after a chemotherapy-induced remission. J Clin Oncol 1990 (8): 416–422.

    PubMed  CAS  Google Scholar 

  52. Gregor A, Morgan PGM, Morgan RL, et al: Small cell carcinoma: combined approach to treatment. Thorax 1979 (34):789–793.

    Article  PubMed  CAS  Google Scholar 

  53. Maurer LH, Tulloh M, Weiss RB, et al: A randomized combined modality trial in small cell carcinoma of the lung. Cancer 1980 (45): 30–39.

    Article  PubMed  CAS  Google Scholar 

  54. Cullen M, Morgan D, Gregory W, et al: Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: a randomized controlled trial. Cancer Chemother Pharmacol 1986 (17):157–160.

    Article  PubMed  CAS  Google Scholar 

  55. Clarke SJ, Bell DR, Woods RL, Levi JA: Maintenance chemotherapy for small cell carcinoma of the lung: long term follow-up. Proc ASCO 1989 (8): 248.

    Google Scholar 

  56. Lebau B, Chastang C, Capron F, et al: Small cell lung cancer: first analysis of a randomized clinical trial of 6 vs 12 chemotherapy cycles for complete responders. Lung Cancer 1988 (4):A100.

    Google Scholar 

  57. Mattson K: Natural alpha interferon as part of a combined treatment for small cell lung cancer. In: Smyth JF (ed) Interferons in Oncology. European School of Oncology Monographs. Springer Verlag, Heidelberg 1987 pp 25–32.

    Google Scholar 

  58. Splinter TAW for the EORTC Lung Cancer Cooperative Group: EORTC 08825: induction versus induction plus maintenance chemotherapy in small cell lung cancer. Definitive evaluation. Proc ASCO 1986 (7): 202.

    Google Scholar 

  59. Spiro SG, Souhami RL, Geddes DM, et al: Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 1989 (59): 578–583.

    Article  PubMed  CAS  Google Scholar 

  60. Bleehen NM, Fayers PM, Girling DJ, et al: Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Br J Cancer 1989 (59): 584–590.

    Article  Google Scholar 

  61. Ettinger DS, Finkelstein DM, Abeloff MD, et al: A randomized comparison of standard chemotherapy versus alternating and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern cooperative oncology group. J Clin Oncol 1990 (8):230–240.

    PubMed  CAS  Google Scholar 

  62. Postmus PE, Berendsen HH, Van Zandwijk N, et al: Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol 1987 (23):1409–1411.

    Article  PubMed  CAS  Google Scholar 

  63. Splinter TAW. Chemotherapy of SCLC: duration of treatment. Lung Cancer 1989 (5):186–195.

    Article  Google Scholar 

  64. Vindelov LL, Hansen HH, Christensen IJ, et al: Clonal heterogeneity of small-cell anaplastic carcinoma of the lung demonstrated by flow-cytometric DNA analysis. Cancer Res 1980 (40):4295–4300.

    PubMed  CAS  Google Scholar 

  65. Roed H, Vindelov LL, Christensen IJ, Spang-Thomsen M, Hansen HH: The cytotoxic activity of cisplatin, carboplatin and teniposide alone and combined determined on four human small cell lung cancer cell lines by clonogenic assay. Eur J Clin Oncol 1988 (24):247–253.

    Article  CAS  Google Scholar 

  66. De Ley L, Postmus PE, Buys CHCM, et al: Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. Cancer Res 1985 (45):6024–6033.

    Google Scholar 

  67. Goldie JH, Coldman AJ, Gudauskas GA: Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 1982 (66): 439–449.

    PubMed  CAS  Google Scholar 

  68. Viallet J, Ihde DC: Systemic therapy for small-cell lung cancer: old themes replayed, new ones awaited. J Clin Oncol 1989 (8):985–987.

    Google Scholar 

  69. Elliot JA, Osterlind K, Hansen HH: Cyclic alternating “non-cross-resistant” chemotherapy in the management of small cell anaplastic carcinoma of the lung. Cancer Treat Rev 1984 (11):103–114.

    Article  Google Scholar 

  70. Daniels JR, Chak LY, Sikic Bl, et al: Chemotherapy of small-cell carcinoma of the lung: a randomized comparison of alternating and sequential combination chemotherapy programs. J Clin Oncol 1984 (2):1192–1199.

    PubMed  CAS  Google Scholar 

  71. Feld R, Evans WK, Coy P, et al: Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol 1987 (5):1401–1409.

    PubMed  CAS  Google Scholar 

  72. Evans WK, Feld R, Murray N, et al: Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. Ann Int Med 1987 (107): 451–458.

    PubMed  CAS  Google Scholar 

  73. Havemann K, Wolf M, Holle R, et al: Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial. Cancer 1987; 59:1072–1082.

    Article  PubMed  CAS  Google Scholar 

  74. Osterlind K, Pedersen AG, Vindelov LL, et al: Alternating or continuous chemotherapy of extensive stage small cell lung cancer. Results of a controlled trial on 204 patients. Lung Cancer 1986 (2):127–128.

    Google Scholar 

  75. Pedersen AG, Osterlind K, Vindelow LL, et al: Alternating or continuous chemotherapy of small cell lung cancer. A three armed randomized trial. Proc ASCO 1987(6):185.

    Google Scholar 

  76. Roth BJ, Johnson DH, Greco FA, et al: A phase III trial of etoposide and cisplatin versus cyclophosphamide, doxorubicin and vincristine, versus alternation of the two therapies for patients with extensive small cell lung cancer: preliminary results. Proc ASCO 1989 (8): 225.

    Google Scholar 

  77. Chahinian AP, Propert KJ, Ware JH, et al: A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the cancer and leukemia group B. J Clin Oncol 1989 (8): 993–1002.

    Google Scholar 

  78. Kristjansen PEG, Pedersen AG, Dombernowsky P, et al: A three-armed randomized trial in small cell lung cancer of two induction regimens containing teniposide and cisplatin or carboplatin followed by alternating chemotherapy versus alternating chemotherapy alone. A preliminary report. Ann Oncol 1990 (1 suppl):51 (abstract).

    Google Scholar 

  79. Postmus PE, Kirkpatrick A, Dalesio O, et al: Two carboplatin-containing regimens for small cell lung cancer: preliminary results of a randomized phase II trial. Cancer Treat Rev 1988 (15):41–44.

    Article  PubMed  Google Scholar 

  80. EORTC lung cancer cooperative group: Evaluation of non-cross resistance of carboplatin containing regimens with cyclophosphamide, doxorubicin and etoposide in patients with small cell lung cancer. EORTC-study 08862. abstr 6.1.63, Interlaken 1988.

    Google Scholar 

  81. Fahra P, Spitzer G, Valdivieso M, et al: High-dose chemotherapy and autologous bone marrow transplantation for the treatment of small-cell lung carcinoma. Cancer 1983 (52):1351–1355.

    Article  Google Scholar 

  82. Souhami RL, Harper PG, Linch D, et al: High-dose cyclophosphamide with autologous marrow transplantation for small cell carcinoma of the bronchus. Cancer Chemother Pharmacol 1983 (10): 205–207.

    Article  PubMed  CAS  Google Scholar 

  83. Souhami RL, Finn G, Gregory WM, et al: High-dose cyclophosphamide in small cell carcinoma of the lung. J Clin Oncol 1985 (3):958–963.

    PubMed  CAS  Google Scholar 

  84. Johnson DH, Wolff SN, Hainsworth JD, et al: Extensive stage small cell bronchogenic carcinoma: intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide. J Clin Oncol 1985 (3): 170–175.

    PubMed  CAS  Google Scholar 

  85. Thatcher N, James RD, Steward WP, et al: Three months’treatment with cyclophosphamide, VP16-213 followed by methotrexate and thoracic radiotherapy for small cell lung cancer. Cancer 1985 (56): 1332–1336.

    Article  PubMed  CAS  Google Scholar 

  86. Thatcher N, Stout R, Smith DB et al: Three months’ treatment with chemotherapy and radiotherapy for small cell lung cancer. Br J Cancer 1985 (52):327–332.

    Article  PubMed  CAS  Google Scholar 

  87. Norton L, Simon R: Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 1977 (61):1307–1317.

    PubMed  CAS  Google Scholar 

  88. Humblet Y, Symann M, Bosly A, et al: Late intensification chemotherapy with autologous bone marrow transplantation in selected small cell carcinoma of the lung: a randomized study. J Clin Oncol 1987 (5):1864–1873.

    PubMed  CAS  Google Scholar 

  89. Williamson S, Taylor C, Crowley J, Taylor S, Miller TP, Giri P: Treatment of small cell lung cancer using an intensive, multidrug, weekly treatment program of short duration. Proc ASCO 1988 (8):751.

    Google Scholar 

  90. Wampler G: A weekly treatment regiment for extensive disease SCLC — a pilot study. Proceedings of the Fifth World Conference on Lung Cancer 1988, Interlaken (Switzerland), abstract no 6.1.22.

    Google Scholar 

  91. Twelves C, Goldman J, Souhami R, et al: Intensive multi-agent chemotherapy in good prognosis small cell lung cancer. Proceedings of the Firth World Conference on Lung Cancer 1988, Interlaken (Switzerland), abstract no 6.1.36.

    Google Scholar 

  92. Soulier JP, Klastersky J, Finet C, Ries F, Sergysels R, Mommen P: Intensive multiple drugs induction chemotherapy for small cell lung cancer: a pilot study. Eur J Cancer Clin Oncol (in press).

    Google Scholar 

  93. Souhami HM, Hamer PG: Intensive weekly chemotherapy for SCLC. Proceedings of the Third lASLC Workshop on SCLC 1989. Elsinore, Denmark, June 18–22 1989.

    Google Scholar 

  94. Taylor CW, Crowley J, Williamson SK, et al: Treatment of SCLC with an alternating chemotherapy regimen given at weekly intervals: a southwest oncology group pilot study. J Clin Oncol 1990 (8):1811–1817.

    PubMed  CAS  Google Scholar 

  95. Osoba D, Murry N, Shah A, Little C, Karsai H, Page R: CODE chemotherapy in extensive stage small cell lung cancer (SCLC). Proc ASCO 1989 (8):854.

    Google Scholar 

  96. Einhorn LH, Pennington K, McClean J: Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier oncology group study. Sem Oncol 1990 (17 suppl 2):32–35.

    CAS  Google Scholar 

  97. Johnson DH, Greco FA, Strupp J, et al: Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: a phase II trial. J Clin Oncol 1990 (8): 1613–1617.

    PubMed  CAS  Google Scholar 

  98. Clark PI, Cottier B, Joel SP, et al. Prolonged administration of single-agent oral etoposide in patients with untreated small cell lung cancer. Proc ASCO 1990 (9):226 (abstract 874).

    Google Scholar 

  99. Postmus PE, Smit EF, Berendsen HH: Phase II study of daily oral etoposide on a 5 week schedule in elderly patients with small cell lung cancer. Ann of Oncol 1990 (1 suppl):54(abstract).

    Google Scholar 

  100. Longo UL, Carbone PP: Chemotherapy administration to the elderly patient. Clinics in Oncology 1985 (4) pp 473–484.

    Google Scholar 

  101. Allan SG, Gregor A, Combleet MA, et al: Phase II trial of vindesine and VP 16-213 in the palliation of poor prognosis patients and elderly patients with small cell lung cancer. Cancer Chemother Pharmacol 1984 (13):106–108.

    Article  PubMed  CAS  Google Scholar 

  102. Cerny T, Lind M, Thatcher N, et al: A simple outpatient treatment with oral ifosfamide and oral etoposide for patients with small cell lung cancer (SCLC). Br J Cancer 1989 (60): 258–261.

    Article  PubMed  CAS  Google Scholar 

  103. Bork E, Ersboll J, Dombernowsky P, et al: Teniposide and etoposide in untreated small cell lung cancer. A randomized study. Ann of Oncol 1990 (1 suppl):53 (abstract).

    Google Scholar 

  104. Postmus PE, Smit EF, Berendsen HH, et al: A feasibility study of testing new drugs for small cell lung cancer in patients with a poor performance status. Cancer Chemother Pharmacol (in press).

    Google Scholar 

  105. Van Hazel GA, Scott M, Eagan RT: The effect of CNS metastases on the survival of patients with small cell cancer of the lung. Cancer 1983 (51):933–937.

    Article  PubMed  Google Scholar 

  106. Kristjansen PE, Hansen HH: Brain metastases from small cell lung cancer treated with combination chemotherapy. Eur J Cancer Clin Oncol 1988 (24): 545–549.

    Article  PubMed  CAS  Google Scholar 

  107. Lee JS, Murphy WK, Glisson BS, et al: Primary chemotherapy of brain metastases in small-cell lung cancer. J Clin Oncol 1989 (7):916–922.

    PubMed  CAS  Google Scholar 

  108. Twelves CJ, Souhami RL, Harper PG, et al: Cerebral metastases in small cell lung cancer respond to systemic chemotherapy. Br J Cancer 1990 (61):147–150.

    Article  PubMed  CAS  Google Scholar 

  109. Vincent M, Evans B, Smith L: First-line chemotherapy rechallenge after relapse in small cell lung cancer. Cancer Chemother Pharmacol 1988 (21):45–48.

    PubMed  CAS  Google Scholar 

  110. Giaccone G, Ferrati P, Donadio M, Testore F, Calicati A: Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 1987 (23):1697–1699.

    Article  PubMed  CAS  Google Scholar 

  111. Giaccone G, Donadio M, Bonardi G, Testore F, Calciati A: Teniposide in the treatment of small cell lung cancer. The influence of prior chemotherapy. J Clin Oncol 1988 (6):1264–1270.

    PubMed  CAS  Google Scholar 

  112. Giaccone G: Second line chemotherapy in SCLC. Lung Cancer 1989 (5):207–213.

    Article  Google Scholar 

  113. Smit EF, Berendsen HH, De Vries EGE, et al: A phase II study of carboplatin and vincristine in previously treated patients with small cell lung cancer. Cancer Chemother Pharmacol 1989 (25):202–204.

    Article  PubMed  CAS  Google Scholar 

  114. Postmus PE, Smit EF, Berendsen HH, et al: Second-line carboplatin-based chemotherapy for small cell lung cancer. The Groningen experience. Sem Oncol (in press).

    Google Scholar 

  115. Nugent JL, Bunn PA, Matthews MJ, et al: CNS metastases in small cell bronchogenic carcinoma. Increasing frequency and changing pattern with lengthening survival. Cancer 1979 (44): 1885–1893.

    Article  PubMed  CAS  Google Scholar 

  116. Hirsch FR, Paulson OB, Hansen HH, Larsen SO: Intracranial metastases in small cell carcinoma of the lung. Prognostic aspects. Cancer 1983 (51):529–533.

    Article  PubMed  CAS  Google Scholar 

  117. Cox JD, Komaki R, Byhardt RW, Kun LE: Results of whole brain irradiation for metastases from small cell carcinoma of the lung. Cancer Treat Rep 1980 (64): 957–961.

    PubMed  CAS  Google Scholar 

  118. Baglan RJ, Marks JE: Comparison of symptomatic and prophylactic irradiation of brain metastases from oat cell carcinoma of the lung. Cancer 1981 (47):41–45.

    Article  PubMed  CAS  Google Scholar 

  119. Lucas CF, Robinson P, Hoskin PJ, et al: Morbidity of cranial relapse in small cell lung cancer and the impact of radiation therapy. Cancer Treat Rep 1986 (70):565–570.

    PubMed  CAS  Google Scholar 

  120. Kleisbauer JP, Vesco D, Orehek J, et al: Treatment of brain metastases of lung cancer with high doses of etoposide (VP16-213). Cooperative study from the groupe francais pneumocancerologie. Eur J Cancer Clin Oncol 1988 (24):131–135.

    Article  PubMed  CAS  Google Scholar 

  121. Postmus PE, Haaxma-Reiche H, Sleijfer DTh, et al: High dose etoposide for brain metastases of small cell lung cancer. A phase II study. Br J Cancer 1989 (59):254–256.

    Article  PubMed  CAS  Google Scholar 

  122. Giaccone G, Donadio M, Bonardi GM, et al: Teniposide (VM26): an effective treatment for brain metastases of small cell carcinoma of the lung. Eur J Cancer Clin Oncol 1988 (24): 629–631.

    Article  PubMed  CAS  Google Scholar 

  123. Postmus PE, Smit EF, Berendsen HH, et al: Treatment of brain metastases of small cell lung cancer with teniposide. Sem Oncol (in press).

    Google Scholar 

  124. Postmus PE, Holthuis JJM, Haaxma-Reiche H, et al: Penetration of VP 16-213 into cerebrospinal fluid after high-dose administration. J Clin Oncol 1984 (2):215–220.

    PubMed  CAS  Google Scholar 

  125. Rosen ST, Aisner J, Makuch RW, et al: Carcinomatous leptomeningitis in small cell lung cancer: A clinicopathological review of the National Cancer Institute experience. Medicine 1982 (61):45–53.

    Article  PubMed  CAS  Google Scholar 

  126. Aisner J, Ostrow S, Govindan S, et al: Leptomeningeal carcinomatosis in small cell carcinoma of the lung. Med Pediatr Oncol 1981 (9): 47–59.

    Article  PubMed  CAS  Google Scholar 

  127. Aroney RS, Dalley DN, Chan WK, et al: Meningeal carcinomatosis in small cell carcinoma of the lung. Am J Med 1981 (71): 26–32.

    Article  PubMed  CAS  Google Scholar 

  128. Postmus PE, Haaxma-Reiche H, Berendsen HH, et al: High-dose etoposide for meningeal carcinomatosis in patients with small cell lung cancer. Eur J Cancer Clin Oncol 1989 (25):377–378.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pulmonary Diseases, University Hospital, Oostersingel 59, 9713, EZ Groningen, The Netherlands

    Pieter E. Postmus

Authors
  1. Pieter E. Postmus
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Colorado Cancer Center, 4200 East Ninth Avenue, Denver, CO, 80262, USA

    Paul A. Bunn Jr. M. D. (Professor of Medicine and Director) (Professor of Medicine and Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Postmus, P.E. (1991). Staging and Treatment for Small Cell Lung Cancer. In: Bunn, P.A. (eds) Current Topics in Lung Cancer. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76784-5_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-76784-5_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-76786-9

  • Online ISBN: 978-3-642-76784-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation